TCGA-E7-A7DU-01A-11R-A32O-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.919842313
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.190
- INTERFERON_ALPHA_RESPONSE+0.130
- CHOLESTEROL_HOMEOSTASIS+0.110
- BILE_ACID_METABOLISM+0.070
- ESTROGEN_RESPONSE_EARLY+0.070
- ESTROGEN_RESPONSE_LATE+0.040
- APICAL_SURFACE+0.020
- OXIDATIVE_PHOSPHORYLATION+0.010
- COAGULATION+0.000
- NOTCH_SIGNALING-0.010
Top 10 suppressed
- E2F_TARGETS-0.470
- G2M_CHECKPOINT-0.460
- PROTEIN_SECRETION-0.440
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.430
- INFLAMMATORY_RESPONSE-0.430
- ANGIOGENESIS-0.400
- MITOTIC_SPINDLE-0.400
- UNFOLDED_PROTEIN_RESPONSE-0.380
- ALLOGRAFT_REJECTION-0.360
- IL6_JAK_STAT3_SIGNALING-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CF-A5U8-01A-11R-A28M-07 | — | — | 0.874 |
| 2 | TCGA-FD-A43X-01A-11R-A23W-07 | — | — | 0.865 |
| 3 | SJEPD001520_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.863 |
| 4 | 308a5759-8930-433f-8d11-4c3da6ed0e29 | — | — | 0.860 |
| 5 | SJEPD007_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.859 |
| 6 | d2c9b21d-0f64-4182-9d5d-82b80a158a1f | — | — | 0.855 |
| 7 | SRR12202498 | — | — | 0.846 |
| 8 | R88 | — | — | 0.844 |
| 9 | SRR650137 | — | — | 0.842 |
| 10 | SRR1319837 | GTEX | — | 0.840 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.190 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.130 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.110 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.070 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.040 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.020 | Temsirolimus | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.010 | Remibrutinib | — uncovered |